The Oklahoma Shared Clinical and Translational Resources

The OSCTR is funded by the National Institutes of Health as part of its IDeA-CTR program. We have the mission to serve as a catalyst for clinical and translational research that improves health and healthcare for underserved and underrepresented populations, to provide training and infrastructure to help junior investigators to launch independent research careers, and to expand the opportunities of IDeA states and Oklahoma communities to participate in research that improves the health of our residents. 

Oklahoma Clinical and Translational Science Institute

 

OCTSI is the home of the OSCTR, as well as clinical research services and dissemination and implementation resources to help improve the delivery of healthcare. 

Oklahoma Primary Healthcare Improvement Cooperative

 

OPHIC is the implementation science arm of a statewide network to help improve healthcare delivery assisting primary care practices to adopt evidence-based best practices for the care of their patients.

OCTSI Clinical Research Unit

​​

The OCTSI CRU assists medical providers to identify and conduct clinical research opportunities in Oklahoma.

​

 

 

 

 

 

EvidenceNOW Grant Initiative Provides Support for Primary Care Practices in Oklahoma to Advance Cardiovascular Care

Submitted by Anonymous (not verified) on

Heart disease remains the number one cause of death in the United States, claiming more lives than all cancers combined. Heart disease is also taking a toll on Oklahoma. But the evidence is clear—we can reduce the threat by applying the ABCS of cardiovascular disease prevention: Aspirin use by high-risk individuals, Blood pressure control, Cholesterol management, and Smoking cessation.

OCTSI receives $15 million grant to improve heart health in Oklahoma

Submitted by Anonymous (not verified) on

OCTSI receives $15 million grant to improve heart health in Oklahoma

Researchers with the University of Oklahoma in Tulsa and Oklahoma City have received a $15 million grant to improve heart health in residents throughout the state.

OU is one of seven grantees in the nation for the award from the U.S. Department of Health and Human Services.

Subscribe to News

Recent Publications

Pharmacotherapy and pulmonary fibrosis risk after SARS-CoV-2 infection: a prospective nationwide cohort study in the United States

Lancet Reg Health Am. 2023 Aug 2;25:100566. doi: 10.1016/j.lana.2023.100566. eCollection 2023 Sep.

ABSTRACT

BACKGROUND: Pulmonary fibrosis is characterized by lung parenchymal destruction and can increase morbidity and mortality. Pulmonary fibrosis commonly occurs following hospitalization for SARS-CoV-2 infection. As there are medications that modify pulmonary fibrosis risk, we investigated whether distinct pharmacotherapies (amiodarone, cancer chemotherapy, corticosteroids, and rituximab) are associated with differences in post-COVID-19 pulmonary fibrosis incidence.

Upcoming Events

Media

Copyright © 2025 The Board of Regents of the University of Oklahoma. All rights reserved
Disclaimer | Copyright | Equal Opportunity Employer

Built and Managed by the OCTSI. Base theme by Zymphonies